N

Nippon Shinyaku Co Ltd
TSE:4516

Watchlist Manager
Nippon Shinyaku Co Ltd
TSE:4516
Watchlist
Price: 5 796 JPY -2.98%
Market Cap: 407.2B JPY

Nippon Shinyaku Co Ltd
Net Issuance of Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Nippon Shinyaku Co Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
N
Nippon Shinyaku Co Ltd
TSE:4516
Net Issuance of Debt
-ÂĄ1.5B
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Net Issuance of Debt
-ÂĄ637.8B
CAGR 3-Years
-51%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Net Issuance of Debt
ÂĄ83.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Otsuka Holdings Co Ltd
TSE:4578
Net Issuance of Debt
-ÂĄ170.8B
CAGR 3-Years
-61%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Chugai Pharmaceutical Co Ltd
TSE:4519
Net Issuance of Debt
-ÂĄ8.2B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Net Issuance of Debt
-ÂĄ208.7B
CAGR 3-Years
-58%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Nippon Shinyaku Co Ltd
Glance View

Market Cap
390.5B JPY
Industry
Pharmaceuticals

Nippon Shinyaku Co., Ltd. stands as a beacon in the Japanese pharmaceutical landscape, weaving a story that begins over a century ago. Originally founded to address the medical needs of its society, the company has strategically evolved its focus, channeling its expertise into two main business domains: pharmaceuticals and functional food. As it carved its niche, Nippon Shinyaku harnessed the power of innovation and research to develop drugs that address critical medical needs, especially in oncology, hematology, and rare diseases. This specialization not only strengthens its foothold but also embodies a moral commitment to enhancing patient quality of life, proving profitable as these fields often present less competition but promise high demand and returns. Alongside its pharmaceutical ventures, Nippon Shinyaku has leveraged the burgeoning wellness trend through its functional food segment, offering products that promote health and prevent disease. This dual approach leverages the company's bioscience expertise and diversifies its revenue streams, shielding it from the volatility often seen in the pharmaceutical sector. By making strategic alliances and collaborations, both domestically and overseas, Nippon Shinyaku accelerates its market penetration and expands its international footprint. As it capitalizes on its robust R&D capabilities, the company anchors its success on a fusion of scientific advancement and strategic acumen, crafting a narrative of resilience and adaptability in a rapidly evolving industry.

Nippon Shinyaku Co Ltd Intrinsic Value
HIDDEN
Show

See Also

What is Nippon Shinyaku Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
-1.5B JPY

Based on the financial report for Jun 30, 2025, Nippon Shinyaku Co Ltd's Net Issuance of Debt amounts to -1.5B JPY.

What is Nippon Shinyaku Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
11%

Over the last year, the Net Issuance of Debt growth was 11%. The average annual Net Issuance of Debt growth rates for Nippon Shinyaku Co Ltd have been 11% over the past three years .

Back to Top